Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters
Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters

Coronavirus China

Shanghai’s Fosun Pharma inks agreement to supply 10 million doses of Covid-19 vaccine to Hong Kong and Macau once approved

  • Fosun Pharma and its German partner BioNTech have signed a letter of intent with a distributor for the supply of 10 million doses of vaccine, provided clinical trials prove successful
  • Fosun has dosed 72 volunteers with BioNTech’s vaccine in a phase-one trial in Jiangsu province, and the preliminary safety data are ‘good’, said CEO Wu Yifang

Topic |   Coronavirus China
Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters
Fosun has agreed to pay BioNTech a licensing fee of up to US$85 million, besides sales royalties of 35 per cent of future annual gross profit. Photo: Reuters
READ FULL ARTICLE